Neogen Chemicals Ltd Valuation Surges to Very Expensive Amid Mixed Returns

Valuation Metrics Reflect Elevated Price Levels

As of 9 April 2026, Neogen Chemicals trades at a price of ₹1,330, up 8.80% from the previous close of ₹1,222.40. Despite this upward momentum, the company’s valuation metrics reveal a stretched price level. The price-to-earnings (P/E) ratio stands at an eye-watering 121.20, a significant premium compared to its peers and historical norms. This P/E ratio places Neogen Chemicals firmly in the “very expensive” category, a downgrade from its previous “expensive” status as of 16 March 2026.

Similarly, the price-to-book value (P/BV) ratio is elevated at 4.39, indicating that investors are paying over four times the company’s net asset value. Other valuation multiples such as EV/EBITDA at 34.59 and EV/EBIT at 43.55 further underscore the premium valuation. These multiples are considerably higher than many of its specialty chemicals peers, signalling that the market is pricing in substantial growth or operational improvements that may not yet be fully realised.

Comparative Peer Analysis Highlights Valuation Disparity

When benchmarked against key competitors in the specialty chemicals space, Neogen Chemicals’ valuation appears stretched. For instance, Navin Fluorine International, also rated “very expensive,” trades at a P/E of 55.26 and EV/EBITDA of 33.39, roughly half Neogen’s P/E multiple. Himadri Speciality Chemical and Sumitomo Chemical, both “very expensive,” have P/E ratios of 33.54 and 37.67 respectively, with EV/EBITDA multiples well below Neogen’s levels.

Even companies rated “fair” such as Deepak Nitrite and Aarti Industries trade at significantly lower multiples, with P/E ratios of 35.88 and 41.23 respectively. This stark contrast suggests that Neogen’s current valuation is an outlier within the sector, raising concerns about potential overvaluation risks.

Financial Performance and Returns Contextualise Valuation

Neogen Chemicals’ return on capital employed (ROCE) and return on equity (ROE) metrics are modest, at 5.93% and 4.41% respectively. These returns are relatively low for a specialty chemicals firm, which typically commands higher capital efficiency. The dividend yield is negligible at 0.08%, offering little income cushion for investors amid the high valuation.

In terms of stock performance, Neogen Chemicals has outperformed the Sensex over the short term, with a 1-week return of 12.09% versus the Sensex’s 6.06%, and a year-to-date return of 12.33% compared to the Sensex’s negative 8.99%. However, over longer horizons, the stock has lagged; it has declined 11.85% over one year and underperformed the Sensex’s 29.63% gain over three years. This mixed performance profile adds complexity to the valuation narrative.

Mojo Score and Grade Reflect Elevated Risk

MarketsMOJO assigns Neogen Chemicals a Mojo Score of 24.0, categorising it as a “Strong Sell.” This represents a downgrade from the previous “Sell” rating issued on 16 March 2026. The downgrade reflects the deteriorating valuation attractiveness and the risk of price correction given the stretched multiples.

The company’s small-cap market capitalisation further compounds risk, as smaller companies tend to exhibit higher volatility and lower liquidity. Investors should weigh these factors carefully against the company’s growth prospects and sector dynamics.

Sector and Market Context

The specialty chemicals sector has generally been characterised by robust demand growth and innovation-driven expansion. However, rising raw material costs, regulatory pressures, and global economic uncertainties have introduced volatility. Within this context, Neogen Chemicals’ valuation premium suggests that the market is pricing in strong future earnings growth or strategic advantages that may not yet be fully evident in current financials.

Investors should also consider the company’s 52-week trading range, which spans from ₹978.00 to ₹1,867.95. The current price of ₹1,330 sits closer to the lower half of this range, despite the very expensive valuation metrics, indicating some price correction potential but also reflecting recent volatility.

Investor Takeaway: Valuation Caution Advisable

Neogen Chemicals Ltd’s recent valuation upgrade to “very expensive” status, combined with its lofty P/E and EV multiples, signals a heightened risk profile for investors. While the stock has demonstrated short-term price strength, its modest returns on capital and equity, alongside a negligible dividend yield, suggest that the premium valuation may not be fully justified by fundamentals at present.

Comparisons with peers reveal that Neogen trades at a significant premium, which could expose it to downside risk should growth expectations not materialise as anticipated. The downgrade to a “Strong Sell” Mojo Grade reinforces the need for caution.

Investors seeking exposure to the specialty chemicals sector might consider evaluating alternative companies with more balanced valuations and stronger financial metrics. Monitoring Neogen Chemicals’ operational performance and sector developments will be crucial to reassessing its investment appeal in the coming quarters.

Summary of Key Valuation Metrics for Neogen Chemicals Ltd

• P/E Ratio: 121.20 (Very Expensive)
• Price to Book Value: 4.39
• EV/EBITDA: 34.59
• ROCE: 5.93%
• ROE: 4.41%
• Dividend Yield: 0.08%
• Mojo Grade: Strong Sell (Downgraded from Sell on 16 Mar 2026)

Given these factors, a prudent approach would be to reassess portfolio allocations and consider valuation-driven risk management strategies when dealing with Neogen Chemicals Ltd.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →